中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
24期
29-30
,共2页
风湿骨痹口服液%急性毒性试验%半数致死量%最大给药量
風濕骨痺口服液%急性毒性試驗%半數緻死量%最大給藥量
풍습골비구복액%급성독성시험%반수치사량%최대급약량
Fengshigubi Oral Liquid%acute toxicity tests%median lethal dose%maximum dose
目的：观察小鼠灌胃风湿骨痹口服液的急性毒性反应，测定半数致死量（ LD50）及最大给药量，为临床安全用药提供依据。方法小鼠给予风湿骨痹口服液灌胃，通过预试验测定 LD50及最大给药量。结果 LD50未测出；小鼠最大给药量为1236 g生药/kg，相当于临床人用量的1799倍，在此剂量下灌胃对小鼠无急性毒性反应。结论风湿骨痹口服液毒性较低，在临床规定用法用量下安全可靠。
目的：觀察小鼠灌胃風濕骨痺口服液的急性毒性反應，測定半數緻死量（ LD50）及最大給藥量，為臨床安全用藥提供依據。方法小鼠給予風濕骨痺口服液灌胃，通過預試驗測定 LD50及最大給藥量。結果 LD50未測齣；小鼠最大給藥量為1236 g生藥/kg，相噹于臨床人用量的1799倍，在此劑量下灌胃對小鼠無急性毒性反應。結論風濕骨痺口服液毒性較低，在臨床規定用法用量下安全可靠。
목적：관찰소서관위풍습골비구복액적급성독성반응，측정반수치사량（ LD50）급최대급약량，위림상안전용약제공의거。방법소서급여풍습골비구복액관위，통과예시험측정 LD50급최대급약량。결과 LD50미측출；소서최대급약량위1236 g생약/kg，상당우림상인용량적1799배，재차제량하관위대소서무급성독성반응。결론풍습골비구복액독성교저，재림상규정용법용량하안전가고。
Objective To observe the acute toxicity reaction of Fengshigubi Oral Liquid by gastric gavage in mice,and to determine LD50 and the maximum dosage to provide the basis for clinical safe medication. Methods The mice were given Fengshigubi Oral Liq-uid by gastric gavage. The median lethal dose( LD50) and the maximum dose were determined by the pre-experiment. Results LD50 was not detected out and the maximum dose in mice was 1 236 g crude drug/kg,which was equivalent to 1 799 times of human dosage in clinic,the gastric gavage of this dose had no acute toxicity in mice. Conclusion Fengshigubi Oral Liquid has low toxicity and it is safe under the clinical provision of usage and dosage.
